Dicerna Pharmaceuticals (DRNA) Receives Media Impact Score of 0.04

Media headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.0776820148929 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Dicerna Pharmaceuticals (DRNA) traded up $0.06 during mid-day trading on Monday, hitting $8.54. The stock had a trading volume of 119,300 shares, compared to its average volume of 176,553. Dicerna Pharmaceuticals has a one year low of $2.42 and a one year high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.22). The company had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The firm’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.68) earnings per share. sell-side analysts forecast that Dicerna Pharmaceuticals will post -3.04 earnings per share for the current year.

Several research analysts have issued reports on DRNA shares. Chardan Capital reaffirmed a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Zacks Investment Research raised Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Monday, October 23rd. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $6.81.

TRADEMARK VIOLATION WARNING: “Dicerna Pharmaceuticals (DRNA) Receives Media Impact Score of 0.04” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/12/04/dicerna-pharmaceuticals-drna-receives-media-impact-score-of-0-04.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply